17,261 trials
Non-Small Cell Lung Cancer · Melanoma · Mismatch Repair-Proficient Colorectal Cancer
Primary: Phase 2: Objective Response Rate (ORR), as Assessed Using Immune Response RECIST (irRECIST) — 22.2; 9.2; 18.9; 5.4 percentage of participants
Epstein-Barr Virus-Associated Lymphoma · Lymphoproliferative Disorders
Primary: Number (Proportion) of Participants With Adverse Events (AEs) — 7; 5; 4; 4 Participants
COVID-19 · Lung Inflammation
Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free
Kidney Failure, Chronic · Kidney Failure, Acute · Heart Failure
Primary: Number of Participants With Acute Kidney Injury During the First 48 Hours After Contrast Administration — 5; 4 Participants
Anxiety Generalized
Primary: Dose Response — -14.23; -15.35; -16.05; -19.22 units on a scale
Heart Failure With Preserved Ejection Fraction
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 23 Participants
Recurrent Head and Neck Cancer
Primary: Safety Measures (Adverse Events and Laboratory Parameters) With Repeat Cycles of Treatment. — 5; 0; 8; 8 Participants
Acute Myeloid Leukemia · Acute Myeloid Leukemia in Remission · Aplastic Anemia
Primary: Overall Survival (OS) — 74 percentage of participants
Mucopolysaccharidosis I
Primary: Number of Participants With Adverse Events — 3; 6; 7; 0 participants
Recurrent Endometrial Endometrioid Adenocarcinoma · Recurrent Uterine Corpus Carcinoma · Stage III Uterine Corpus Cancer AJCC v7
Primary: Clinical Activity of Combination Enzalutamide, Carboplatin and Paclitaxel Represented as Objective Tumor Response (Complete Response (CR) + Partial Response (PR)). — 68…
AML · CMML · MDS
Primary: Safety Assessed by Adverse Events — 3; 3; 4; 4 participants
Recurrent Colorectal Carcinoma · Progressive Colorectal Carcinoma
Primary: Safety and Maximum Tolerated Dosage of Imprime PGG When Used in Combination With Cetuximab With or Without Irinotecan Therapy — 3; 7; 4; 9 participants
Social Anxiety Disorder
Primary: Change From Baseline to the Average Subjective Units of Distress Scale (SUDS) Score of the 5-minute Performance Phase of a Public Speaking Challenge — 22.42; 24.26…
Frown Lines
Primary: Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 1 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the…
Dry Eye Disease
Primary: University of North Carolina Dry Eye Management Scale (UNC DEMS) Responder Analysis — 65.4; 90.0; 66.0; 71.4 percentage of responders — p=0.0040